MyD88: At the Heart of Inflammatory Signaling and Cardiovascular Disease

Overview

Journal J Mol Cell Cardiol

Specialty Cardiology & Vascular Diseases

Date 2021 Aug 9

PMID 34371036

Citations 28

Authors

Abraham L Bayer

Pilar Alcaide

Affiliations

Soon will be listed here.

Abstract

Cardiovascular disease is a leading cause of death worldwide and is associated with systemic inflammation. In depth study of the cell-specific signaling mechanisms mediating the inflammatory response is vital to improving anti-inflammatory therapies that reduce mortality and morbidity. Cellular damage in the cardiovascular system results in the release of damage associated molecular patterns (DAMPs), also known as "alarmins," which activate myeloid cells through the adaptor protein myeloid differentiation primary response 88 (MyD88). MyD88 is broadly expressed in most cell types of the immune and cardiovascular systems, and its role often differs in a cardiovascular disease context and cell specific manner. Herein we review what is known about MyD88 in the setting of a variety of cardiovascular diseases, discussing cell specific functions and the relative contributions of MyD88-dependent vs. independent alarmin triggered inflammatory signaling. The widespread involvement of these pathways in cardiovascular disease, and their largely unexplored complexity, sets the stage for future in depth mechanistic studies that may place MyD88 in both immune and non-immune cell types as an attractive target for therapeutic intervention in cardiovascular disease.

Citing Articles

Atherosclerosis: A Comprehensive Review of Molecular Factors and Mechanisms.

Tasouli-Drakou V, Ogurek I, Shaikh T, Ringor M, DiCaro M, Lei K Int J Mol Sci. 2025; 26(3).

PMID: 39941130 PMC: 11818631. DOI: 10.3390/ijms26031364.

Discovery of Innate Immune Response mRNAs That Are Impacted by Structure-Specific Oral Baker's Yeast Beta Glucan Consumption.

McFARLIN B, Curtis J, Vingren J, Hill D, Bridgeman E BioTech (Basel). 2025; 14(1.

PMID: 39846553 PMC: 11755543. DOI: 10.3390/biotech14010004.

MicroRNA profiling of the feline left heart identifies chamber-specific expression signatures in health and in advanced hypertrophic cardiomyopathy.

Joshua J, Caswell J, Monne Rodriguez J, Kipar A, OSullivan M, Wood G J Mol Cell Cardiol Plus. 2025; 4():100037.

PMID: 39801693 PMC: 11708362. DOI: 10.1016/j.jmccpl.2023.100037.

In vitro and ex vivo screening of microRNA combinations with enhanced cell penetrating peptides to stimulate intervertebral disc regeneration.

Ni Neill T, Barcellona M, Wilson N, OBrien F, Dixon J, Curtin C JOR Spine. 2024; 7(4):e1366.

PMID: 39726900 PMC: 11669629. DOI: 10.1002/jsp2.1366.

Engineered macrophages: an "Intelligent Repair" cellular machine for heart injury.

Zhang Z, Du H, Gao W, Zhang D Cell Regen. 2024; 13(1):25.

PMID: 39592532 PMC: 11599506. DOI: 10.1186/s13619-024-00209-7.

References

Zheng D, Zang Y, Xu H, Wang Y, Cao X, Wang T . MicroRNA-214 promotes the calcification of human aortic valve interstitial cells through the acceleration of inflammatory reactions with activated MyD88/NF-κB signaling. Clin Res Cardiol. 2018; 108(6):691-702. DOI: 10.1007/s00392-018-1398-9. View

Jarrett M, Yao Q, Venardos N, Weyant M, Reece T, Meng X . Simvastatin down-regulates osteogenic response in cultured human aortic valve interstitial cells. J Thorac Cardiovasc Surg. 2020; 161(4):e261-e271. DOI: 10.1016/j.jtcvs.2019.10.081. View

Bartfai T, Margarita Behrens M, Gaidarova S, Pemberton J, Shivanyuk A, Rebek Jr J . A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses. Proc Natl Acad Sci U S A. 2003; 100(13):7971-6. PMC: 164697. DOI: 10.1073/pnas.0932746100. View

Gorelik M, Lee Y, Abe M, Andrews T, Davis L, Patterson J . IL-1 receptor antagonist, anakinra, prevents myocardial dysfunction in a mouse model of Kawasaki disease vasculitis and myocarditis. Clin Exp Immunol. 2019; 198(1):101-110. PMC: 6718290. DOI: 10.1111/cei.13314. View

Singh R, Haka A, Asmal A, Barbosa-Lorenzi V, Grosheva I, Chin H . TLR4 (Toll-Like Receptor 4)-Dependent Signaling Drives Extracellular Catabolism of LDL (Low-Density Lipoprotein) Aggregates. Arterioscler Thromb Vasc Biol. 2019; 40(1):86-102. PMC: 6928397. DOI: 10.1161/ATVBAHA.119.313200. View

Richer M, Lavallee D, Shanina I, Horwitz M . Toll-like receptor 3 signaling on macrophages is required for survival following coxsackievirus B4 infection. PLoS One. 2009; 4(1):e4127. PMC: 2606033. DOI: 10.1371/journal.pone.0004127. View

Zheng X, Sun C, Liu Q, Lu X, Fu L, Liang G . Compound LM9, a novel MyD88 inhibitor, efficiently mitigates inflammatory responses and fibrosis in obesity-induced cardiomyopathy. Acta Pharmacol Sin. 2020; 41(8):1093-1101. PMC: 7468329. DOI: 10.1038/s41401-020-0410-x. View

Hulsmans M, Clauss S, Xiao L, Aguirre A, King K, Hanley A . Macrophages Facilitate Electrical Conduction in the Heart. Cell. 2017; 169(3):510-522.e20. PMC: 5474950. DOI: 10.1016/j.cell.2017.03.050. View

Liu L, Wang Y, Cao Z, Wang M, Liu X, Gao T . Up-regulated TLR4 in cardiomyocytes exacerbates heart failure after long-term myocardial infarction. J Cell Mol Med. 2015; 19(12):2728-40. PMC: 4687701. DOI: 10.1111/jcmm.12659. View

10.

Anwar M, Shah M, Kim J, Choi S . Recent clinical trends in Toll-like receptor targeting therapeutics. Med Res Rev. 2018; 39(3):1053-1090. PMC: 6587958. DOI: 10.1002/med.21553. View

11.

Bomfim G, Echem C, Martins C, Costa T, Sartoretto S, Dos Santos R . Toll-like receptor 4 inhibition reduces vascular inflammation in spontaneously hypertensive rats. Life Sci. 2014; 122:1-7. PMC: 4790807. DOI: 10.1016/j.lfs.2014.12.001. View

12.

Strassheim D, Dempsey E, Gerasimovskaya E, Stenmark K, Karoor V . Role of Inflammatory Cell Subtypes in Heart Failure. J Immunol Res. 2019; 2019:2164017. PMC: 6745095. DOI: 10.1155/2019/2164017. View

13.

Lundberg A, Ketelhuth D, Johansson M, Gerdes N, Liu S, Yamamoto M . Toll-like receptor 3 and 4 signalling through the TRIF and TRAM adaptors in haematopoietic cells promotes atherosclerosis. Cardiovasc Res. 2013; 99(2):364-73. DOI: 10.1093/cvr/cvt033. View

14.

Lai C, Wang K, Lee F, Tsai H, Ma C, Cheng T . Toll-Like Receptor 4 Is Essential in the Development of Abdominal Aortic Aneurysm. PLoS One. 2016; 11(1):e0146565. PMC: 4711799. DOI: 10.1371/journal.pone.0146565. View

15.

Richards M, Black A, Bonnet D, Barish G, Woo C, Tabas I . The LPS2 mutation in TRIF is atheroprotective in hyperlipidemic low density lipoprotein receptor knockout mice. Innate Immun. 2012; 19(1):20-9. PMC: 3434265. DOI: 10.1177/1753425912447130. View

16.

Williams J, Huang L, Randolph G . Cytokine Circuits in Cardiovascular Disease. Immunity. 2019; 50(4):941-954. PMC: 6924925. DOI: 10.1016/j.immuni.2019.03.007. View

17.

Chen L, Chen H, Chen P, Zhang W, Wu C, Sun C . Development of 2-amino-4-phenylthiazole analogues to disrupt myeloid differentiation factor 88 and prevent inflammatory responses in acute lung injury. Eur J Med Chem. 2018; 161:22-38. DOI: 10.1016/j.ejmech.2018.09.068. View

18.

Yang J, Zhang X, Yang J, Ding J, Liu Z, Li S . The cardioprotective effect of fluvastatin on ischemic injury via down-regulation of toll-like receptor 4. Mol Biol Rep. 2010; 38(5):3037-44. DOI: 10.1007/s11033-010-9970-z. View

19.

Salvador B, Arranz A, Francisco S, Cordoba L, Punzon C, Llamas M . Modulation of endothelial function by Toll like receptors. Pharmacol Res. 2016; 108:46-56. DOI: 10.1016/j.phrs.2016.03.038. View

20.

Riad A, Westermann D, Escher F, Becher P, Savvatis K, Lettau O . Myeloid differentiation factor-88 contributes to TLR9-mediated modulation of acute coxsackievirus B3-induced myocarditis in vivo. Am J Physiol Heart Circ Physiol. 2010; 298(6):H2024-31. DOI: 10.1152/ajpheart.01188.2009. View